ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Chronic myeloid leukemia (CML) is the first human malignancy to be successfully treated with a small molecule inhibitor, imatinib, targeting a mutant oncoprotein (BCR-ABL).